drugset
drugset / Trial / NCT02598570

Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma

NCT02598570 ↗

Phase 1 Completed 7 enrolled AbbVie Infinity Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This study seeks to evaluate the safety and pharmacokinetics of duvelisib in Japanese participants with relapsed or refractory lymphoma.

Timeline

Start
2015-11
Primary completion
2016-12
Completion
2017-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Duvelisib Small molecule — Oral

Indications

lymphoma